Quinn Opportunity Partners’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Quinn Opportunity Partners’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-26,438	Closed	-$107K	–	204
2019 Q4	$107K	Sell	26,438 -52,000	-66%	-$180K	0.01%	157
2019 Q3	$339K	Buy	78,438 +10,000	+15%	+$40K	0.04%	134
2019 Q2	$273K	Hold	68,438	–	–	0.03%	148
2019 Q1	$367K	Sell	68,438 -18,284	-21%	-$118K	0.05%	133
2018 Q4	$445K	Buy	86,722 +19,284	+29%	+$146K	0.06%	107
2018 Q3	$654K	Buy	67,438 +10,000	+17%	+$101K	0.09%	106
2018 Q2	$586K	Hold	57,438	–	–	0.08%	114
2018 Q1	$747K	Buy	+57,438	New	+$855K	0.1%	105

Other funds holding PRTK

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Quinn Opportunity Partners's PRTK Position: Q1 2020 in Review

Quinn Opportunity Partners sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q1 2020, closing a stake of 26,438 shares — an estimated $107K sold.

Quinn Opportunity Partners first reported a position in PRTK in Q1 2018 and held it in 8 quarters. The position peaked at $747K in Q1 2018. 85 funds tracked by Wall St. Rank hold PRTK as of Q1 2020.

Quinn Opportunity Partners reported no remaining Paratek Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
Quinn Opportunity Partners sold 26,438 Paratek Pharmaceuticals, Inc. shares in Q1 2020, an estimated $107K.
Quinn Opportunity Partners first reported a position in Paratek Pharmaceuticals, Inc. in Q1 2018 and held it in 8 quarters.
Quinn Opportunity Partners's Paratek Pharmaceuticals, Inc. position peaked at $747K in Q1 2018.
85 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q1 2020.

Based on Quinn Opportunity Partners's 13F filing for Q1 2020, filed 12 May 2020.